All In Biotech

Drug Trial Radar · NCT07766473

First in Human Study of BETA-TT8 in wetAge-related Macular Degeneration (wetAMD)

A Phase Ib/IIa, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, and Exploratory Activity of BETA-TT8 Ophthalmic Gel 3.8% in Patients With Neovascular (Wet) Age-related Macular Degeneration (wetAMD)

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Mar 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Filamon LTDIndustry
Sponsor type
Industry
First posted
Aug 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human clinical trial evaluating the safety and tolerability of BETA-TT8 Ophthalmic Gel in people with wet age-related macular degeneration (AMD). Approximately 24 participants with stable wet AMD who have previously received at least three anti- Vascular Endothelial Growth Factor (anti -VEGF) injections will use the eye gel for up to 12 weeks at one of three dosing schedules (once, twice, or three times daily). Standard anti-VEGF treatment (aflibercept) will remain available if needed during the study. Participants who complete the initial 12-week treatment period may be invited to continue in an extension phase for up to 12 months to collect additional safety and treatment information.

Conditions

  • Neovascular (Wet) Age-Related Macular Degeneration

Interventions

  • BETA-TT8 ophthalmic gel 3.8% w/vDrug

    A selective small-molecule inhibitor of the MEK/ERK (MAPK) signalling pathway, topical ophthalmic gel.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety of topical BETA-TT8 based on TEAEs.Time frame: 12 weeks
  2. To evaluate the safety of topical BETA-TT8 based on DLTs.Time frame: 12 weeks
  3. To evaluate the safety of topical BETA-TT8 based on clinically significant ocular findings.Time frame: 12 weeks
  4. To evaluate the safety of topical BETA-TT8 based on intraocular pressure changes.Time frame: 12 weeks
  5. To evaluate the safety of topical BETA-TT8 based on corneal staining abnormalities.Time frame: 12 weeks
  6. To evaluate the tolerability of topical BETA-TT8 based on reasons for discontinuations.Time frame: 12 weeks
  7. To evaluate the safety of topical BETA-TT8 based on TEAEs.Time frame: 12 weeks
  8. To evaluate the safety of topical BETA-TT8 based on TEAEs.Time frame: 12 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Central Coast Eye Specialist

    Gosford, New South Wales, Australia

  • Sydney Eye Hospital

    Sydney, New South Wales, Australia

  • Sydney West Retina

    Westmead, New South Wales, Australia

  • Cerulea Clinical Trials

    East Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.